First NDA in. Regional deal done. Now Myovant has PhIII data to back up relugolix's push to another blockbuster market

Amber Tong

With two NDAs in prostate cancer and uterine fibroids lined up, Myovant has taken the first step toward a third indication for relugolix by unveiling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

First NDA in. Regional deal done. Now Myovant has PhIII data to back up relugolix's push to another blockbuster market

Amber Tong

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

First NDA in. Re­gion­al deal done. Now My­ovant has PhI­II da­ta to back up re­l­u­golix's push to an­oth­er block­buster mar­ket

Amber Tong

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

First NDA in. Regional deal done. Now Myovant has PhIII data to back up relugolix's push to another blockbuster market

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva